WEIGHT & METABOLIC RESEARCH
A long-acting amylin receptor agonist studied for enhanced satiety beyond GLP-1 agonists alone.
Cagrilintide is a long-acting amylin receptor agonist (non-selective for amylin and calcitonin receptors). Phase 3 trials, including monotherapy data, have reported promising weight-loss results, with stronger effects observed in combination approaches. It is positioned as a next-generation satiety compound and remains investigational.
Included because it has completed Phase 3 human trials and a clearly defined amylin-pathway mechanism, while its real-world research use is still developing. It reflects strong evidence that is not yet matched by an established use history.
Enhances satiety and reduces food intake through amylin/calcitonin receptors in the brainstem and hypothalamus.
Slows gastric emptying to prolong post-meal fullness and suppresses postprandial glucagon release.
Modeled as synergistic with GLP-1 agonists for amplified appetite control.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
Cagrilintide is investigational and not FDA-approved. Phase 3 clinical data has been reported. Sold and offered strictly for laboratory and research use.
